Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of GDC-0310 in Healthy Volunteers
NCT02742779Phase 1Completed
- Sponsor
- Genentech
- Start
- Sep 2015
- Primary completion
- Jun 2017
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GDC-0310 in pain (10 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs). Started Sep 2015; status: completed.
02
Drugs
GDC-0310
03
Conditions
pain
Beyond the preview
Go deeper on NCT02742779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02742779.